A groundbreaking new study published in Nature’s npj Metabolic Health and Disease has found that retatrutide — the triple-agonist drug commonly called “GLP-3” — dramatically reduced cancer tumor growth in two types of cancer, far outperforming the single-agonist drug semaglutide (Ozempic).
The findings suggest that the same triple-action mechanism that makes GLP-3 more effective for weight loss may also provide powerful anti-cancer benefits — benefits that persisted even after the drug was stopped and weight was regained.
Here is what the study found, why it matters, and what it means for people considering GLP-3 for weight management.
Disclosure: This post contains affiliate links. If you purchase through our links, we earn a small commission at no extra cost to you.
The Study: Retatrutide vs Semaglutide in Cancer Models
Researchers at Vanderbilt University and the University of Pennsylvania tested retatrutide (the GLP-3 triple agonist) against semaglutide (the GLP-1 single agonist in Ozempic) in pre-clinical models of two aggressive cancers: pancreatic ductal adenocarcinoma (pancreatic cancer) and lung adenocarcinoma (lung cancer).
The study, authored by Sandesh Marathe, Liza Makowski, and colleagues from multiple institutions, was published on March 14, 2025 in npj Metabolic Health and Disease (DOI: 10.1038/s44324-025-00054-5).
The Key Findings — And They Are Stunning
Pancreatic Cancer Results
Retatrutide produced a 14-fold reduction in tumor volume compared to untreated controls
Semaglutide (Ozempic) produced only a 4-fold reduction — meaning retatrutide was roughly 3.5 times more effective at shrinking pancreatic tumors
Tumor onset was significantly delayed in the retatrutide group
Tumor engraftment (the ability of cancer to take hold) was reduced — tumors failed to engraft 33% of the time in retatrutide-treated subjects
Lung Cancer Results
Retatrutide produced a 17-fold reduction in tumor volume compared to controls
Tumor engraftment was reduced by 50% — half the time, lung cancer simply could not establish itself
Tumor onset was significantly delayed
Tumor progression was dramatically slowed
The Most Remarkable Finding: Anti-Cancer Benefits Lasted After Stopping
Perhaps the most striking result: when retatrutide was withdrawn and subjects regained weight, the anti-cancer benefits persisted. The metabolic benefits (blood sugar, insulin resistance) reversed with weight regain — but the tumor suppression remained durable.
This suggests that retatrutide does not just suppress cancer through weight loss alone. It appears to reprogram the immune system in a lasting way.
How Does Retatrutide Fight Cancer? The Immune Connection
The researchers found that retatrutide induced significant immune reprogramming — both throughout the body and specifically within the tumor microenvironment:
Elevated circulating IL-6 — a pro-inflammatory cytokine that helps activate anti-cancer immune responses
Increased antigen-presenting cells — immune cells that help the body identify and target cancer
Reduced immunosuppressive cells — fewer of the cells that cancer uses to hide from the immune system
Activation of pro-inflammatory pathways — essentially waking up the immune system to recognize and attack tumors
In simple terms: retatrutide does not just help you lose weight. It appears to reprogram your immune system to be better at finding and fighting cancer — and that reprogramming lasts even after the drug is stopped.
The triple-agonist mechanism does not just produce more weight loss — it appears to trigger fundamentally different biological responses, including immune system changes that have anti-cancer effects independent of weight loss itself.
What This Means for You
This is pre-clinical research, not a completed human trial. But the implications are significant:
Obesity and cancer are deeply linked — over 40% of U.S. adults are obese, and obesity is associated with at least 13 types of cancer. Addressing weight is addressing cancer risk.
The triple-agonist approach (GLP-3) outperformed the single-agonist approach (GLP-1) dramatically — not just for weight loss, but for cancer outcomes. This validates the theory that activating all three pathways produces fundamentally better results.
Immune reprogramming may have lasting benefits — even if you stop treatment or regain some weight, the immune system changes may provide ongoing protection.
Natural GLP-3 support becomes more compelling — if activating these three pathways provides both weight management AND immune benefits, supporting them through any means — pharmaceutical or natural — becomes a higher priority for long-term health.
The Natural GLP-3 Angle
Pharmaceutical retatrutide is still in clinical trials and not yet available by prescription. But this research reinforces why the triple-pathway approach matters — and why natural GLP-3 supplements that support GLP-1, GIP, and glucagon pathways are gaining attention.
While natural supplements have not been studied for anti-cancer effects, the principle is the same: supporting your body’s natural hormone production across all three pathways may provide broader health benefits than targeting just one.
For those of us who take a self-reliant approach to health, this study is one more reason to pay attention to metabolic health, weight management, and the tools — natural or otherwise — that help us stay ahead of preventable disease.
Title: Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression
Journal: npj Metabolic Health and Disease (Nature Publishing Group)
Published: March 14, 2025
DOI: 10.1038/s44324-025-00054-5
Researchers: Sandesh J. Marathe, Emily W. Grey, Margaret S. Bohm, Sydney C. Joseph, Arvind V. Ramesh, Matthew A. Cottam, Kamran Idrees, Kathryn E. Wellen, Alyssa H. Hasty, Jeffrey C. Rathmell, Liza Makowski
Institutions: Vanderbilt University, University of Pennsylvania
